
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
PARTICIPANTSMarcia Glynn, MD Assistant Professor, Dermatology Director, PediatricDermatology Martin Luther King/Charles R. Drew Medical Center Los Angeles,CaliforniaJudy Hunter, MD Pediatrician Principal Investigator HealthCare PartnersMedical Group Torrance, California